Literature DB >> 24696728

Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.

Jun Xiao1, Guojian Li2, Shuhan Lin3, Ke He1, Hao Lai1, Xianwei Mo1, Jiansi Chen1, Yuan Lin1.   

Abstract

We aim to investigate the clinical characteristics and prognostic factors of Hepatocellular Carcinoma (HCC) patients treated by transarterial chemoembolization (TACE) in Chinese cohort. A total of 2,493 HCC patients treated by TACE were included in this retrospective study. Patients were divided into the younger group (n=1,877) or the elderly group (n=616) based upon their ages (cut-off value of 60 y/o). Chi-square test or Wilcoxon rank-sum test was used to compare patients' characteristics. Univariate and multivariate analysis were used to determine prognostic factors. When compared with the younger group, the elderly group had lower male/female ratio and family liver disease history ratio, as well as advanced stage or Child-Pugh grade B patients. The median survival time was 8 months and 27 months for the younger and the elderly group, respectively. The 1-, 2-, and 3-year survival rates in the younger group and the elderly group were 31.82%, 12.5%, 6.53%, and 84.66%, 53.28%, 28.39%, respectively. Multivariate analysis showed that HBV infection, AFP value, TNM stage, Child-Pugh class, portal vein tumor thrombus (PVTT) and tumor number were independent prognostic factors for the younger patients; the elderly ones had similar independent prognostic factors except for HBV infection. The elderly group had lower male/female ratio and family history ratio, as well as advanced stage or Child-Pugh grade B patients. The elderly seems to have better prognosis than the younger ones, which is probably related to the fact that the elderly have lower tumor burden and better liver function.

Entities:  

Keywords:  Clinical characteristics; TACE; hepatocellular carcinoma; prognostic factor

Mesh:

Year:  2014        PMID: 24696728      PMCID: PMC3971316     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  32 in total

1.  Hepatocellular carcinoma in older adults: clinical features, treatments, and survival.

Authors:  Sang Hyub Lee; Hyun Cheul Choi; Sook-Hyang Jeong; Kwang Ho Lee; Jae Il Chung; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Nayoung Kim; Dong Ho Lee; Ho Cheol Choi; Chang Jin Yoon; Sung Gwon Kang
Journal:  J Am Geriatr Soc       Date:  2011-01-28       Impact factor: 5.562

2.  Management of hepatocellular carcinoma.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

3.  Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.

Authors:  Christos S Georgiades; Kelvin Hong; Michael D'Angelo; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2005-12       Impact factor: 3.464

4.  Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors.

Authors:  Mirko Olivo; Franco Valenza; Antonio Buccellato; Lorenza Scala; Roberto Virdone; Elio Sciarrino; Sonia Di Piazza; Ciro Marrone; Ambrogio Orlando; Giorgio Fusco; Salvatore Madonia; Mario Cottone
Journal:  Dig Liver Dis       Date:  2009-11-13       Impact factor: 4.088

5.  Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Carol E A Peña; Chetan D Lathia; Michael Shan; Gerold Meinhardt; Jordi Bruix
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

6.  [The efficacy and prognosis of transcatheter chemoembolization for hepatocellular carcinoma in the elderly].

Authors:  Y Hoshida; K Ikeda; S Saito; M Kobayashi; M Kobayashi; Y Suzuki; A Tsubota; I Koida; Y Arase; N Murashima; K Chayama; H Kumada
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1999-02

7.  Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma.

Authors:  Ja Young Kang; Moon Seok Choi; Sue Jin Kim; Jae Sook Kil; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Korean J Hepatol       Date:  2010-12

8.  Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management.

Authors:  R T Poon; S T Fan; C M Lo; C L Liu; H Ngan; I O Ng; J Wong
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma.

Authors:  Vishnudutt Purohit; Rao Rapaka; Oh Sang Kwon; B J Song
Journal:  Life Sci       Date:  2012-10-30       Impact factor: 5.037

10.  Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma.

Authors:  Rohit Loomba; Jessica Liu; Hwai-I Yang; Mei-Hsuan Lee; Sheng-Nan Lu; Li-Yu Wang; Uchenna H Iloeje; San-Lin You; David Brenner; Chien-Jen Chen
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-10       Impact factor: 11.382

View more
  14 in total

1.  Expression of Girdin in primary hepatocellular carcinoma and its effect on cell proliferation and invasion.

Authors:  Ke Cao; Can Lu; Shuang Han; Qiong Zou; Jingjing Li; Dingfang Xie; Siqi He; Li Yu; Jianda Zhou; Xiaowei Peng; Peiguo Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.

Authors:  Lucas C Adam; Lynn J Savic; Julius Chapiro; Brian Letzen; MingDe Lin; Christos Georgiades; Kelvin K Hong; Nariman Nezami
Journal:  Clin Imaging       Date:  2022-06-26       Impact factor: 2.420

3.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 4.  Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Ke-Vin Chang; Jin-De Chen; Wei-Ting Wu; Kuo-Chin Huang; Chia-Tzu Hsu; Der-Sheng Han
Journal:  Liver Cancer       Date:  2017-12-09       Impact factor: 11.740

5.  Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma.

Authors:  Daisuke Yasui; Satoru Murata; Shiro Onozawa; Takahiko Mine; Tatsuo Ueda; Fumie Sugihara; Chiaki Kawamoto; Eiji Uchida; Shin-ichiro Kumita
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

6.  Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification.

Authors:  Jiang-feng Xu; Xi-yu Liu; Shuai Wang; Huai-xi Wen
Journal:  World J Surg Oncol       Date:  2015-02-28       Impact factor: 2.754

7.  The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma.

Authors:  Dou-Sheng Bai; Chi Zhang; Ping Chen; Sheng-Jie Jin; Guo-Qing Jiang
Journal:  Sci Rep       Date:  2017-10-09       Impact factor: 4.379

8.  A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Sadahisa Ogasawara; Tetsuhiro Chiba; Yoshihiko Ooka; Naoya Kanogawa; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Ryosaku Azemoto; Masami Shinozaki; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

9.  Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells.

Authors:  Hai-Bo Xing; Meng-Ting Tong; Jing Wang; Hong Hu; Chong-Ya Zhai; Chang-Xin Huang; Da Li
Journal:  Biomed Res Int       Date:  2018-03-06       Impact factor: 3.246

10.  Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment.

Authors:  Yao Liu; Dongying Xue; Xiaogang Zhang; Fangyuan Gao; Le Sun; Xue Yang; Yuxin Li; Qun Zhang; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Xianbo Wang
Journal:  Biomed Res Int       Date:  2020-02-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.